Lee Morten Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.15 M
as on 12-12-2024
- Paid Up Capital ₹ 0.15 M
as on 12-12-2024
- Company Age 9 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
as on 12-12-2024
- Revenue 40.40%
(FY 2022)
- Profit 9.32%
(FY 2022)
- Ebitda 461.59%
(FY 2022)
- Net Worth 77.10%
(FY 2022)
- Total Assets 25.39%
(FY 2022)
About Lee Morten Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.15 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹1.00 M.
Surjith Kuttiozhathil, Upputhungal Suthish, Hareesh Palliappath, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232KL2015PTC039220
- Company No.
039220
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Sep 2015
- Date of AGM
04 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kozhikode, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Lee Morten Life Sciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surjith Kuttiozhathil  | Director | 21-Sep-2015 | Current |
| Upputhungal Suthish | Director | 21-Sep-2015 | Current |
| Hareesh Palliappath | Director | 21-Sep-2015 | Current |
| Koyattu Rajan | Director | 21-Sep-2015 | Current |
| Kuttiozhathil Arunjith | Director | 21-Sep-2015 | Current |
Financial Performance of Lee Morten Life Sciences.
Lee Morten Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 40.4% increase. The company also saw a slight improvement in profitability, with a 9.32% increase in profit. The company's net worth Soared by an impressive increase of 77.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lee Morten Life Sciences?
In 2021, Lee Morten Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 May 2016 | ₹1.00 M | Open |
How Many Employees Work at Lee Morten Life Sciences?
Unlock and access historical data on people associated with Lee Morten Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lee Morten Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lee Morten Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
